Year of Award:
Molecular & Cellular Analysis Technologies
Other PI or Project Leader:
A'as [pronounced Ah z], in collaboration with Cornell University and Weill Cornell Medical College, aims to commercialize a solar-powered and smartphone-integrated system for performing nucleic acid- based analysis of Kaposi's sarcoma herpesvirus in limited resource settings. Our 'KS-Detect' system comprises of (1) an instrument that performs PCR through solar heating of a microfluidic chip, (2) a small traveling case that contains the instrument and can be carried by a clinician to the patient, and (3) a smartphone 'app' that reads the on-chip temperatures, operates sample flow inside the chip, and interprets the fluorescence signal of the sample to provide the user with the test results. KS is one of the most prevalent cancers in sub-Saharan Africa and is associated with high mortality rates. Often, patients are not diagnosed until they develop later stages of the disease, when available therapeutics lose much of their potency. In the absence of immunohistochemistry, polymerase chain reaction (PCR) identification of Kaposi's sarcoma-associated herpesvirus (KSHV) in skin biopsies represents the most reliable method of diagnosing a patient. Unfortunately, existing technologies cannot address the needs associated with biopsy based nucleic acid screening in limited resource settings. As part of the $1.3B nucleic acid test market, new instruments must be cost effective and portable in order to provide early on-site diagnosis for those who cannot access care at centralized facilities. The technologies behind KS-Detect, which were developed at Cornell University, allow PCR-based diagnostics to be performed on tissue samples in the field without the need for expensive equipment or reliable electrical power. This is achieved through the incorporation of 'lab-on-a-syringe' tissue processing, solar thermal PCR, and smartphone-based operation and diagnostics. A prototype was built and tested in Kenya and Uganda in early 2014. In Phase I we will ruggedize the current system and perform validation tests using pseudo- biopsies. With NIH support we will focus on a four-stage path to market plan that involves: (1) Technology development building off preliminary results, (2) Human trials in collaboration with Weill Cornell, AMPATH and the Infectious Diseases Institute, (3) System deployment in large-scale human studies, and (4) Product release to healthcare providers and other foundations.